Gonadal Hormones, Diseases, and Emerging Therapeutics

Chapter
Part of the Topics in Bone Biology book series (TBB, volume 7)

Abstract

Gonadal steroids play a critical role in bone metabolism throughout life. Not only are they essential for normal bone mass accrual and development during adolescence, but they also are critical in the maintenance of bone health through adult and senior life. In this chapter, discussion of normal gonadal hormone synthesis will be reviewed, and commonly encountered disease states and therapies will be considered for both men and women. We will initiate the discussion with disorders that occur at the level of the target organs, the testes and ovaries, and then consider defects of the pituitary and hypothalamus. Discussion will focus on common disorders of primary and secondary hypogonadism in men and women, including their diagnosis and therapeutic strategies for treatment of these diseases.

Key words

Gonadal hormones Androgens Hypogonadism Testosterone Estrogen Klinefelter syndrome 

References

  1. 1.
    Classic pages in obstetrics and gynecology by Henry H. Turner. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology. 1938;23: 566–74. Am J Obstet Gynecol 113: 279, 1972.Google Scholar
  2. 2.
    Achermann JC, Jameson J. Disorders of sex development. In: Fauci AS, Braunwald E, Kasper DL, Kauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. New York: McGraw-Hill; 2008. Access medicine.Google Scholar
  3. 3.
    Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest. 1997;99:1699–703.PubMedCrossRefGoogle Scholar
  4. 4.
    Amundson E, Boman UW, Barrenas ML, Bryman I, Landin-Wilhelmsen K. Impact of growth hormone therapy on quality of life in adults with turner syndrome. J Clin Endocrinol Metab. 2010;95:1355–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Andrade AC, Baron J, Manolagas SC, Shaw NJ, Rappold GA, Donaldson MD, Gault EJ, Savendahl L. Hormones and genes of importance in bone physiology and their influence on bone mineralization and growth in Turner syndrome. Horm Res Paediatr. 2010;73:161–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Bakalov VK, Bondy CA. Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord. 2008;9:145–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Bakalov VK, Chen ML, Baron J, Hanton LB, Reynolds JC, Stratakis CA, Axelrod LE, Bondy CA. Bone mineral density and fractures in Turner syndrome. Am J Med. 2003;115:259–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Bassil N. Late-onset hypogonadism. Med Clin North Am. 2011;95:507–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Bechtold S, Rauch F, Noelle V, Donhauser S, Neu CM, Schoenau E, Schwarz HP. Musculoskeletal analyses of the forearm in young women with Turner syndrome: a study using peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2001;86:5819–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Bojesen A, Birkebaek N, Kristensen K, Heickendorff L, Mosekilde L, Christiansen JS, Gravholt CH. Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporos Int. 2011;22(5):1441–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Bojesen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab. 2006;91:1254–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Borjesson AE, Lagerquist MK, Liu C, Shao R, Windahl SH, Karlsson C, Sjogren K, Moverare-Skrtic S, Antal MC, Krust A, Mohan S, Chambon P, Savendahl L, Ohlsson C. The role of estrogen receptor alpha in growth plate cartilage for longitudinal bone growth. J Bone Miner Res. 2010;25:2690–700.PubMedCrossRefGoogle Scholar
  13. 13.
    Breuil V, Euller-Ziegler L. Gonadal dysgenesis and bone metabolism. Joint Bone Spine. 2001;68:26–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Callewaert F, Venken K, Ophoff J, De Gendt K, Torcasio A, van Lenthe GH, Van Oosterwyck H, Boonen S, Bouillon R, Verhoeven G, Vanderschueren D. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J. 2009;23:232–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337:91–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, Thambundit A, Avbelj M, Dhruvakumar S, Plummer L, Hughes VA, Seminara SB, Boepple PA, Sidis Y, Crowley Jr WF, Martin KA, Hall JE, Pitteloud N. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med. 2011;364:215–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Christo K, Prabhakaran R, Lamparello B, Cord J, Miller KK, Goldstein MA, Gupta N, Herzog DB, Klibanski A, Misra M. Bone metabolism in ­adolescent athletes with amenorrhea, athletes with eumenorrhea, and control subjects. Pediatrics. 2008;121:1127–36.PubMedCrossRefGoogle Scholar
  18. 18.
    Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys. 2010;503:118–28.PubMedCrossRefGoogle Scholar
  19. 19.
    Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67:604–6.PubMedGoogle Scholar
  20. 20.
    Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20:358–417.PubMedCrossRefGoogle Scholar
  21. 21.
    Dang ZC, van Bezooijen RL, Karperien M, Papapoulos SE, Lowik CW. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res. 2002;17:394–405.PubMedCrossRefGoogle Scholar
  22. 22.
    Davies MC, Gulekli B, Jacobs HS. Osteoporosis in Turner’s syndrome and other forms of primary amenorrhoea. Clin Endocrinol (Oxf). 1995;43:741–6.CrossRefGoogle Scholar
  23. 23.
    Bremner WJ, Matsumoto AM, Sussman AM, Paulsen CA. Follicle stimulating hormone and spermatogenesis. J Clin Invest. 1981;68:1044–1052.Google Scholar
  24. 24.
    DiVasta AD, Gordon CM. Bone health in adolescents. Adolesc Med Clin. 2006;17:639–52; abstract xi.PubMedGoogle Scholar
  25. 25.
    Dufau ML, Catt KJ. Gonadotropin receptors and regulation of steroidogenesis in the testis and ovary. Vitam Horm. 1978;36:461–592.PubMedCrossRefGoogle Scholar
  26. 26.
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111:1221–30.PubMedGoogle Scholar
  27. 27.
    Ferlin A, Schipilliti M, Di Mambro A, Vinanzi C, Foresta C. Osteoporosis in Klinefelter’s syndrome. Mol Hum Reprod. 2010;16:402–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Ferlin A, Schipilliti M, Foresta C. Bone density and risk of osteoporosis in Klinefelter syndrome. Acta Paediatr. 2011;100:878–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferretti JL, Cointry GR, Capozza RF, Frost HM. Bone mass, bone strength, muscle-bone interactions, osteopenias and osteoporoses. Mech Ageing Dev. 2003;124:269–79.PubMedCrossRefGoogle Scholar
  30. 30.
    Gibson JH, Mitchell A, Harries MG, Reeve J. Nutritional and exercise-related determinants of bone density in elite female runners. Osteoporos Int. 2004;15:611–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Gordon CM. Bone density issues in the adolescent gynecology patient. J Pediatr Adolesc Gynecol. 2000;13:157–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol. 1998;51:147–58.PubMedCrossRefGoogle Scholar
  34. 34.
    Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab. 2002;87:2798–808.PubMedCrossRefGoogle Scholar
  35. 35.
    Andersson AM. Inhibin B in the assessment of ­seminiferous tubular function. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:389 /contents/evaluation-of-male-infertility/abstract/78.Google Scholar
  36. 36.
    Grinspoon S, Miller K, Coyle C, Krempin J, Armstrong C, Pitts S, Herzog D, Klibanski A. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab. 1999;84:2049–55.PubMedCrossRefGoogle Scholar
  37. 37.
    Hanton L, Axelrod L, Bakalov V, Bondy CA. The importance of estrogen replacement in young women with Turner syndrome. J Womens Health (Larchmt). 2003;12:971–7.CrossRefGoogle Scholar
  38. 38.
    Hayes FJ, DeCruz S, Seminara SB, Boepple PA, Crowley Jr WF. Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J Clin Endocrinol Metab. 2001;86:53–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Ho AY, Kung AW. Determinants of peak bone mineral density and bone area in young women. J Bone Miner Metab. 2005;23:470–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:4367–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology. 2001;142:3800–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996;2:1132–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Imai Y, Youn MY, Kondoh S, Nakamura T, Kouzmenko A, Matsumoto T, Takada I, Takaoka K, Kato S. Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad Sci. 2009;1173 Suppl 1:E31–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Ishizaka K, Suzuki M, Kageyama Y, Kihara K, Yoshida K. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. Asian J Androl. 2002;4:117–21.PubMedGoogle Scholar
  45. 45.
    Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88–91.PubMedCrossRefGoogle Scholar
  46. 46.
    Johnston Jr CC, Slemenda CW. Determinants of peak bone mass. Osteoporos Int. 1993;3 Suppl 1:54–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Karlsson MK, Weigall SJ, Duan Y, Seeman E. Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa. J Clin Endocrinol Metab. 2000;85:3177–82.PubMedCrossRefGoogle Scholar
  48. 48.
    Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology. 2008;149:5984–95.PubMedCrossRefGoogle Scholar
  49. 49.
    Khastgir G, Studd JW, Fox SW, Jones J, Alaghband-Zadeh J, Chow JW. A longitudinal study of the effect of subcutaneous estrogen replacement on bone in young women with Turner’s syndrome. J Bone Miner Res. 2003;18:925–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Khosla S. Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. Bone. 2008;43:414–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem. 1996;271:28890–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Kimble RB, Vannice JL, Bloedow DC, Thompson RC, Hopfer W, Kung VT, Brownfield C, Pacifici R. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest. 1994;93:1959–67.PubMedCrossRefGoogle Scholar
  53. 53.
    Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest. 1994;94:2397–406.PubMedCrossRefGoogle Scholar
  54. 54.
    Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719–30.PubMedGoogle Scholar
  55. 55.
    Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest. 2003;111:1651–64.PubMedGoogle Scholar
  56. 56.
    Kubler A, Schulz G, Cordes U, Beyer J, Krause U. The influence of testosterone substitution on bone mineral density in patients with Klinefelter’s syndrome. Exp Clin Endocrinol. 1992;100:129–32.PubMedCrossRefGoogle Scholar
  57. 57.
    Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf). 1999;51:497–502.CrossRefGoogle Scholar
  58. 58.
    Lanes R, Gunczler P, Esaa S, Martinis R, Villaroel O, Weisinger JR. Decreased bone mass despite long-term estrogen replacement therapy in young women with Turner’s syndrome and previously normal bone density. Fertil Steril. 1999;72:896–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Lawson EA, Donoho D, Miller KK, Misra M, Meenaghan E, Lydecker J, Wexler T, Herzog DB, Klibanski A. Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J Clin Endocrinol Metab. 2009;94:4710–6.PubMedCrossRefGoogle Scholar
  60. 60.
    LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, Hoffman AR, Laughlin G, Ohlsson C, Orwoll ES. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94:3337–46.PubMedCrossRefGoogle Scholar
  61. 61.
    Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305–11.PubMedCrossRefGoogle Scholar
  62. 62.
    Martin K, Santoro N, Hall J, Filicori M, Wierman M, Crowley Jr WF. Clinical review 15: management of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab. 1990;71:1081A–G.PubMedCrossRefGoogle Scholar
  63. 63.
    Migliaccio S, Newbold RR, Bullock BC, Jefferson WJ, Sutton Jr FG, McLachlan JA, Korach KS. Alterations of maternal estrogen levels during gestation affect the skeleton of female offspring. Endocrinology. 1996;137:2118–25.PubMedCrossRefGoogle Scholar
  64. 64.
    Mircea CN, Lujan ME, Pierson RA. Metabolic fuel and clinical implications for female reproduction. J Obstet Gynaecol Can. 2007;29:887–902.PubMedGoogle Scholar
  65. 65.
    Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26:27–34.PubMedCrossRefGoogle Scholar
  66. 66.
    Molina P. Chapter9: Female reproductive system. In: Molina PE, editor. Endocrine physiology. 3rd ed. New York: McGraw-Hill; 2009.Google Scholar
  67. 67.
    Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female ­siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689–98.PubMedCrossRefGoogle Scholar
  68. 68.
    Neely EK, Marcus R, Rosenfeld RG, Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab. 1993;76:861–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Nichols JF, Rauh MJ, Barrack MT, Barkai HS. Bone mineral density in female high school athletes: interactions of menstrual function and type of mechanical loading. Bone. 2007;41:371–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Nichols JF, Rauh MJ, Lawson MJ, Ji M, Barkai HS. Prevalence of the female athlete triad syndrome among high school athletes. Arch Pediatr Adolesc Med. 2006;160:137–42.PubMedCrossRefGoogle Scholar
  71. 71.
    O’Connell MD, Roberts SA, Srinivas-Shankar U, Tajar A, Connolly MJ, Adams JE, Oldham JA, Wu FC. Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab. 2011;96:454–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings SR. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166:2124–31.PubMedCrossRefGoogle Scholar
  73. 73.
    Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL, Spelsberg TC. Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology. 1991;129:3313–20.PubMedCrossRefGoogle Scholar
  74. 74.
    Oursler MJ, Pederson L, Fitzpatrick L, Riggs BL, Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA. 1994;91:5227–31.PubMedCrossRefGoogle Scholar
  75. 75.
    Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA. 1991;88:5134–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Pallais JC, Au M, Au M, Seminara S, Crowley Jr WF. Kallmann syndrome. Seattle: University of Washington; 2007.Google Scholar
  77. 77.
    Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg TC, Riggs BL, Oursler MJ. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA. 1999;96:505–10.PubMedCrossRefGoogle Scholar
  78. 78.
    Pitsillides AA, Rawlinson SC, Suswillo RF, Bourrin S, Zaman G, Lanyon LE. Mechanical strain-induced NO production by bone cells: a possible role in adaptive bone (re)modeling? FASEB J. 1995;9:1614–22.PubMedGoogle Scholar
  79. 79.
    Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley Jr WF. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87:4128–36.PubMedCrossRefGoogle Scholar
  80. 80.
    Rautava E, Lehtonen-Veromaa M, Kautiainen H, Kajander S, Heinonen OJ, Viikari J, Mottonen T. The reduction of physical activity reflects on the bone mass among young females: a follow-up study of 142 adolescent girls. Osteoporos Int. 2007;18:915–22.PubMedCrossRefGoogle Scholar
  81. 81.
    Reindollar RH, Novak M, Tho SP, McDonough PG. Adult-onset amenorrhea: a study of 262 patients. Am J Obstet Gynecol. 1986;155:531–43.PubMedGoogle Scholar
  82. 82.
    Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA. 1991;265:1133–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an endocrine society ­position statement. J Clin Endocrinol Metab. 2007;92:405–13.PubMedCrossRefGoogle Scholar
  84. 84.
    Ross JL, Kowal K, Quigley CA, Blum WF, Cutler Jr GB, Crowe B, Hovanes K, Elder FF, Zinn AR. The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Leri-Weill dyschondrosteosis and Turner syndrome. J Pediatr. 2005;147:499–507.PubMedCrossRefGoogle Scholar
  85. 85.
    Ross JL, Long LM, Feuillan P, Cassorla F, Cutler Jr GB. Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner’s syndrome. J Clin Endocrinol Metab. 1991;73:355–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Ross JL, Long LM, Loriaux DL, Cutler Jr GB. Growth hormone secretory dynamics in Turner syndrome. J Pediatr. 1985;106:202–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Saenger P. Turner’s syndrome. N Engl J Med. 1996;335:1749–54.PubMedCrossRefGoogle Scholar
  88. 88.
    Santen RJ. Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men? J Clin Invest. 1975;56:1555–63.PubMedCrossRefGoogle Scholar
  89. 89.
    Santoro N, Filicori M, Crowley Jr WF. Hypogo­nadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocr Rev. 1986;7:11–23.PubMedCrossRefGoogle Scholar
  90. 90.
    Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841–50.PubMedCrossRefGoogle Scholar
  91. 91.
    Seeman E, Szmukler GI, Formica C, Tsalamandris C, Mestrovic R. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res. 1992;7:1467–74.PubMedCrossRefGoogle Scholar
  92. 92.
    Seo JT, Lee JS, Oh TH, Joo KJ. The clinical significance of bone mineral density and testosterone levels in Korean men with non-mosaic Klinefelter’s syndrome. BJU Int. 2007;99:141–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA. 2000;97:7829–34.PubMedCrossRefGoogle Scholar
  94. 94.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–19.PubMedCrossRefGoogle Scholar
  95. 95.
    Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056–61.PubMedCrossRefGoogle Scholar
  96. 96.
    Sowers MF. Lower peak bone mass and its decline. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:317–29.PubMedCrossRefGoogle Scholar
  97. 97.
    Sowinska-Przepiera E, Chelstowski K, Friebe Z, Syrenicz A. Bone mineral density in girls with functional hypothalamic amenorrhea subjected to estroprogestagen treatment – a 4-year prospective study. Gynecol Endocrinol. 2011;27(11):966–70.PubMedCrossRefGoogle Scholar
  98. 98.
    Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast ­formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001;276:8836–40.PubMedCrossRefGoogle Scholar
  99. 99.
    Stepan JJ, Burckhardt P, Hana V. The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter’s syndrome: the influence of vitamin D deficiency and hormonal status. Bone. 2003;33:589–96.PubMedCrossRefGoogle Scholar
  100. 100.
    Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA. Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab. 2005;90:6516–22.PubMedCrossRefGoogle Scholar
  101. 101.
    Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest. 1993;91:257–63.PubMedCrossRefGoogle Scholar
  102. 102.
    Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997;82:3128–35.PubMedCrossRefGoogle Scholar
  103. 103.
    Van der Werff ten Bosch JJ, Bot A. Some skeletal dimensions of males with isolated gonadotrophin deficiency. Neth J Med. 1992;41:259–63.PubMedGoogle Scholar
  104. 104.
    Wahlstrom T, Huhtaniemi I, Hovatta O, Seppala M. Localization of luteinizing hormone, follicle-stimulating hormone, prolactin, and their receptors in human and rat testis using immunohistochemistry and radioreceptor assay. J Clin Endocrinol Metab. 1983;57:825–30.PubMedCrossRefGoogle Scholar
  105. 105.
    Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG. Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab. 2002;87:3162–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.PubMedCrossRefGoogle Scholar
  107. 107.
    Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, Guerra R, Kushner H, Schwartz S, Sybert VP, Van Dyke DL, Ross JL. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. Am J Hum Genet. 1998;63:1757–66.PubMedCrossRefGoogle Scholar
  108. 108.
    Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003;26:76–83.PubMedCrossRefGoogle Scholar
  109. 109.
    Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in Turner syndrome: a pilot study. J Clin Endocrinol Metab. 2009;94:4820–7.PubMedCrossRefGoogle Scholar
  110. 110.
    Zuckerman-Levin N, Yaniv I, Schwartz T, Guttmann H, Hochberg Z. Normal bone mineral density but frail cortical bone in Turner’s syndrome. Clin Endocrinol (Oxf). 2007;67:60–4.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2012

Authors and Affiliations

  1. 1.Division of Endocrinology and Metabolism, Department of MedicineUniversity of Connecticut Health CenterFarmingtonUSA
  2. 2.Yale Department of MedicineYale New Haven HospitalNew HavenUSA

Personalised recommendations